OCUGEN INC. - COMMON STOCK

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

15 май 2024 05:30:00 Источник Nasdaq GlobeNewswire

Ocugen Provides Business Update with First Quarter 2024 Financial Results

14 май 2024 07:00:25 Источник Nasdaq GlobeNewswire

Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

10 май 2024 15:05:06 Источник Nasdaq GlobeNewswire

Ocugen to Present at May 2024 Investor Conferences

10 май 2024 06:45:07 Источник Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

03 май 2024 06:30:05 Источник Nasdaq GlobeNewswire

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

02 май 2024 06:15:46 Источник Nasdaq GlobeNewswire

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

29 апр 2024 05:45:00 Источник Nasdaq GlobeNewswire

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 апр 2024 08:05:24 Источник Nasdaq GlobeNewswire

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 апр 2024 05:30:40 Источник Nasdaq GlobeNewswire

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

19 апр 2024 06:13:05 Источник Nasdaq GlobeNewswire

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

12 апр 2024 06:30:34 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

10 апр 2024 06:02:26 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

08 апр 2024 05:30:43 Источник Nasdaq GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

05 апр 2024 06:02:21 Источник Nasdaq GlobeNewswire

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

02 апр 2024 07:00:39 Источник Nasdaq GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

01 апр 2024 17:08:46 Источник Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

01 апр 2024 16:43:45 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

18 мар 2024 05:30:50 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

13 мар 2024 07:00:54 Источник Nasdaq GlobeNewswire

Ocugen to Present at Investing in Cures Summit

06 мар 2024 06:30:09 Источник Nasdaq GlobeNewswire